Eisai files for full FDA approval for Alzheimer’s drug Leqembi

The logo of Eisai Co Ltd is displayed at the company headquarters in Tokyo, Japan, March 8, 2018. REUTERS/Issei Kato/File Photo

• Companies

• Eisai Co LtdFollow
• Biogen IncFollow
• U.S. Food and Drug AdministrationFollow

Jan 6 (Reuters) – Japanese drugmaker Eisai Co Ltd (4523.T) said on Saturday it had submitted an application to the U.S. Food and Drug Administration for a standard review of its Alzheimer's drug Leqembi, which was recently approved under the agency's accelerated review process.

Read Next / Editor's Picks

• Future of HealthcategoryExclusive: China in talks with Pfizer for generic COVID drug – sources, article with image12:59 AM UTC
• GalleryFuture of HealthcategoryEisai, Biogen receives U.S. FDA approval for Alzheimer's drug, applies for full approval, article with gallery6:10 AM UTC . Updated undefined ago
• ApprovalscategoryFactbox: Who can get the newly approved Eisai and Biogen Alzheimer's drug?, article with imageJanuary 6, 2023
• VideoGovernmentcategoryNow able to sell abortion pill, U.S. pharmacies weigh if they should, article with videoJanuary 6, 2023

Source reuters.com